Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COVID-19 mitigation behaviors and policies limited SARS-CoV-2 transmission in the United States from September 2020 through November 2021

View ORCID ProfileVelma K. Lopez, Sarah Kada, Pragati V. Prasad, Taylor Chin, Betsy L. Cadwell, Jessica M. Healy, Rachel B. Slayton, Matthew Biggerstaff, Michael A. Johansson
doi: https://doi.org/10.1101/2023.07.19.23292882
Velma K. Lopez
1National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector Borne Diseases, Centers for Disease Control and Prevention (CDC)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Velma K. Lopez
  • For correspondence: oko8{at}cdc.gov
Sarah Kada
1National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector Borne Diseases, Centers for Disease Control and Prevention (CDC)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pragati V. Prasad
2National Center for Immunization and Respiratory Diseases, Influenza Division, CDC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Taylor Chin
1National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector Borne Diseases, Centers for Disease Control and Prevention (CDC)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Betsy L. Cadwell
3Global Health Center, Division Global Health Protection, CDC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica M. Healy
4NCEZID, Division of Healthcare Quality Promotion, CDC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel B. Slayton
4NCEZID, Division of Healthcare Quality Promotion, CDC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Biggerstaff
2National Center for Immunization and Respiratory Diseases, Influenza Division, CDC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael A. Johansson
1National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector Borne Diseases, Centers for Disease Control and Prevention (CDC)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

United States’ jurisdictions implemented varied policies to slow SARS-CoV-2 transmission. Understanding patterns of these policies alongside individual’s behaviors can inform effective outbreak response. To do so, we estimated the time-varying reproduction number (Rt), a weekly measure of real-time transmission using US COVID-19 cases from September 2020-November 2021. We then assessed the association between Rt and policies, personal COVID-19 mitigation behaviors, variants, immunity, and social vulnerability indicators using two multi-level regression models. First, we fit a model with state-level policy stringency according to the Oxford Stringency Index, a composite indicator reflecting the strictness of COVID-19 policies and strength of pandemic-related communication. Our second model included a subset of specific policies. We found that personal mitigation behaviors and vaccination were more strongly associated with decreased transmission than policies. Importantly, transmission was reduced not by a single measure, but by various layered measures. These results underscore the need for policy, behavior change, and risk communication integration to reduce virus transmission during epidemics.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All data are available in the main text or the supplementary materials. COVID-19 case data are available upon request at https://data.cdc.gov/Case-Surveillance/COVID-19-Case-Surveillance-Restricted-Access-Detai/mbd7-r32t. All other data are in the public domain and referenced in the Supplemental Text. R code is available in a public repository (https://github.com/cdcepi/COVID-19-Mitigation_Rt).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Back to top
PreviousNext
Posted July 23, 2023.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19 mitigation behaviors and policies limited SARS-CoV-2 transmission in the United States from September 2020 through November 2021
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
COVID-19 mitigation behaviors and policies limited SARS-CoV-2 transmission in the United States from September 2020 through November 2021
Velma K. Lopez, Sarah Kada, Pragati V. Prasad, Taylor Chin, Betsy L. Cadwell, Jessica M. Healy, Rachel B. Slayton, Matthew Biggerstaff, Michael A. Johansson
medRxiv 2023.07.19.23292882; doi: https://doi.org/10.1101/2023.07.19.23292882
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
COVID-19 mitigation behaviors and policies limited SARS-CoV-2 transmission in the United States from September 2020 through November 2021
Velma K. Lopez, Sarah Kada, Pragati V. Prasad, Taylor Chin, Betsy L. Cadwell, Jessica M. Healy, Rachel B. Slayton, Matthew Biggerstaff, Michael A. Johansson
medRxiv 2023.07.19.23292882; doi: https://doi.org/10.1101/2023.07.19.23292882

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)